The World Health Organization reported 2,073 cases and 796 deaths in the Democratic Republic of Congo, marking the epidemic’s critical stage and making it the third-largest Ebola outbreak recorded at that point. Caused by Bundibugyo virus, the outbreak was declared on 15 May 2026 and spread across eight provinces, with transmission concentrated in the east. More than 80% of new infections were reported outside known contact lists, a sign of how difficult it has been to trace transmission chains. WHO declared a Public Health Emergency of International Concern on 17 May, citing the outbreak’s scale and international implications, with epidemiological uncertainty also a factor. Bundibugyo virus differs from the Zaire ebolavirus responsible for earlier major outbreaks, so vaccines and treatments developed for Zaire Ebola cannot automatically be considered effective or approved for this strain.
In an update at the time, WHO Director-General Tedros Adhanom Ghebreyesus said the situation had deteriorated rapidly since the government declared the epidemic two months earlier. Cases topped 2,000 in a fraction of the time it took during the 2018 to 2019 outbreak, raising concern among health agencies and local authorities. The epidemic later grew far beyond that early tally: the European Centre for Disease Prevention and Control recorded 9,637 confirmed cases and 4,646 related deaths in the DRC by 20 October 2026. A U.S. Centers for Disease Control and Prevention summary listed 9,704 confirmed cases and 4,687 deaths by 22 October.
Ituri remains the basic centre of transmission. WHO reported 7,040 confirmed cases and 3,271 deaths there by 20 October, with cases identified in 28 of the province’s 36 health zones. North Kivu had 2,146 confirmed cases and 1,199 deaths in the same reporting period; its reported case-fatality ratio was 55.9%. The outbreak’s broad reach and continued transmission have made it difficult to identify and isolate every case. The response has scaled up significantly: treatment capacity exceeds 800 beds, diagnostic laboratories have expanded from one to sixteen, and contact-tracing effectiveness is approaching 80%. More than 21,000 community workers are being trained to support the response.
Clinical research is tackling the lack of countermeasures specifically established for Bundibugyo-virus disease. WHO’s PARTNERS trial began enrolling patients in the DRC on 2 July to evaluate MBP134, a monoclonal antibody, and remdesivir, an antiviral, both separately and in combination. A separate trial, Tumaini, began in Bunia, Ituri, using ring vaccination to study vaccination of high-risk contacts around confirmed cases. Candidates under investigation include Oxford’s ChAdOx1-BDBV and a Moderna mRNA vaccine, as well as rVSV-based candidates developed by IAVI and PHV. Minapharm’s MVA-CR19 is also under investigation. The Tumaini trial has also been reported to evaluate Ervebo, licensed against Zaire Ebola, alongside Bundibugyo-virus vaccine candidates; its Zaire Ebola approval does not establish approval or effectiveness against Bundibugyo virus. A post-exposure prophylaxis trial with obeldesivir has also begun for exposed people who are not yet symptomatic. These therapies and Bundibugyo vaccine candidates remain investigational. In the earlier reported tally, 377 patients had recovered, underscoring the importance of early diagnosis and safe care.
There have also been signs of progress beyond Congo’s borders. In neighboring Uganda, the last confirmed Ebola patient was discharged, starting a 42-day countdown to the official declaration of the end of the outbreak there. Uganda’s containment measures limited the reported impact to 20 cases and two deaths, a stark contrast with the situation in the DRC. International agencies have continued monitoring the risk of further cross-border spread. The ECDC described a multi-country outbreak involving the DRC, alongside Kenya and Nigeria. The regional response has drawn attention to the importance of rapid intervention and cross-border cooperation, themes also explored in recent coverage of emergency management, such as the debate over wildfire response in Almería.
For Spain and other European countries, developments in Central Africa highlight the persistent threat posed by infectious diseases and the need for strong public health systems. The outbreak remains concentrated in the DRC and has spread across multiple provinces. International monitoring of possible exportation shows why cross-border surveillance remains impressive. Clinical trials and international cooperation may help shape future epidemic response strategies in Africa and globally.
